HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.

Abstract
In acute-type leukemia, no method for the prediction of relapse following allogeneic stem cell transplantation based on minimal residual disease (MRD) levels is established yet. In the present study, MRD in 72 cases of allogeneic transplantation for acute myeloid leukemia, acute lymphoid leukemia, and chronic myeloid leukemia (accelerated phase or blast crisis) was monitored frequently by quantitating the transcript of WT1 gene, a "panleukemic MRD marker," using reverse transcriptase-polymerase chain reaction. Based on the negativity of expression of chimeric genes, the background level of WT1 transcripts in bone marrow following allogeneic transplantation was significantly decreased compared with the level in healthy volunteers. The probability of relapse occurring within 40 days significantly increased step-by-step according to the increase in WT1 expression level (100% for 1.0 x 10(-2)-5.0 x 10(-2), 44.4% for 4.0 x 10(-3)-1.0 x 10(-2), 10.2% for 4.0 x 10(-4)-4.0 x 10(-3), and 0.8% for < 4.0 x 10(-4)) when WT1 level in K562 was defined as 1.0). WT1 levels in patients having relapse increased exponentially with a constant doubling time. The doubling time of the WT1 level in patients for whom the discontinuation of immunosuppressive agents or donor leukocyte infusion was effective was significantly longer than that for patients in whom it was not (P <.05). No patients with a short doubling time of WT1 transcripts (< 13 days) responded to these immunomodulation therapies. These findings strongly suggest that the WT1 assay is very useful for the prediction and management of relapse following allogeneic stem cell transplantation regardless of the presence of chimeric gene markers.
AuthorsHiroyasu Ogawa, Hiroya Tamaki, Kazuhiro Ikegame, Toshihiro Soma, Manabu Kawakami, Akihiro Tsuboi, Eui Ho Kim, Naoki Hosen, Masaki Murakami, Tatsuya Fujioka, Tomoki Masuda, Yuki Taniguchi, Sumiyuki Nishida, Yusuke Oji, Yoshihiro Oka, Haruo Sugiyama
JournalBlood (Blood) Vol. 101 Issue 5 Pg. 1698-704 (Mar 01 2003) ISSN: 0006-4971 [Print] United States
PMID12406915 (Publication Type: Evaluation Study, Journal Article)
Chemical References
  • Neoplasm Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • WT1 Proteins
Topics
  • Acute Disease
  • Blast Crisis (blood, genetics, pathology, therapy)
  • Gene Expression Regulation, Leukemic
  • Genes, Wilms Tumor
  • Humans
  • K562 Cells (metabolism)
  • Leukemia (blood, genetics, pathology, therapy)
  • Leukemia, Myeloid, Accelerated Phase (blood, genetics, pathology, therapy)
  • Neoplasm Proteins (biosynthesis, genetics)
  • Neoplasm, Residual (diagnosis)
  • Peripheral Blood Stem Cell Transplantation
  • Predictive Value of Tests
  • RNA, Messenger (biosynthesis)
  • RNA, Neoplasm (biosynthesis)
  • Recurrence
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transcription, Genetic
  • Transplantation, Homologous
  • Treatment Outcome
  • WT1 Proteins (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: